EXACOS EG Population - EXACOS EG

Study identifier:D5980R00101

ClinicalTrials.gov identifier:NCT06983340

EudraCT identifier:N/A

CTIS identifier:N/A

Will Be Recruiting

Official Title

Exacerbations and their Outcomes in Egyptian Patients (EXACOS EG Population): Understanding the burden of severe exacerbations of COPD and the association between frequency of severe exacerbations and clinical and health-care utilization outcomes in less well-resourced countries: Sample of Egyptian Patients.

Medical condition

Chronic Obstructive Pulmonary Disease

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

240

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 30 Aug 2025
Estimated Primary Completion Date: 31 Dec 2025
Estimated Study Completion Date: 31 Dec 2025

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jul 2025 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria